Yedidya Idit, Elbaz Greener Gabby, Vaturi Mordehay, Sagie Alik, Amir Offer, Carasso Shemy, Monakier Daniel
Department of Cardiology, Rabin Medical Center, Beilinson Hospital, Petach Tikva 4941492, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6329302, Israel.
J Clin Med. 2022 Dec 9;11(24):7325. doi: 10.3390/jcm11247325.
Background: Disopyramide is a class Ia antiarrhythmic drug that has been used for the second-line treatment of symptomatic hypertrophic obstructive cardiomyopathy (HOCM). The aim of the study was to assess the impact of short-acting disopyramide in patients with hypertrophic obstructive cardiomyopathy (HOCM) using two-dimensional speckle-tracking echocardiography. Methods: This prospective study included patients with HOCM on chronic treatment with short-acting disopyramide. Two sequential comprehensive echocardiographic examinations were performed: after temporary disopyramide suspension and 2.5 h after disopyramide intake. Results: 19 patients were included in the study. The effect of disopyramide on the left ventricle was not uniform. After the intake of disopyramide, the mean global strain peak was −17 ± 2% before disopyramide intake and −14 ± 2% after (p < 0.0001). There was a significant reduction in strain in the basal septal (p = 0.015), basal inferior (p = 0.019), basal posterior (p = 0.05), apical anterior (p = 0.0001), and apical lateral segments (p = 0.021). In all other segments, there was no significant change. Disopyramide also caused a significant accentuation of the base-apex strain gradients (p = 0.036). No change was noted in circumferential and left atrial strain. While the left ventricular ejection fraction and outflow gradients did not change, the significant reduction in global and segmental longitudinal strain demonstrated the acute negative inotropic effect of disopyramide on the myocardium in patients with HOCM. Conclusion: A strain analysis may be a useful tool to assess the negative inotropic effect of cardiovascular medication on the left ventricle in patients with HOCM.
丙吡胺是一种Ia类抗心律失常药物,已用于有症状的肥厚性梗阻性心肌病(HOCM)的二线治疗。本研究的目的是使用二维斑点追踪超声心动图评估短效丙吡胺对肥厚性梗阻性心肌病(HOCM)患者的影响。方法:这项前瞻性研究纳入了接受短效丙吡胺长期治疗的HOCM患者。进行了两次连续的全面超声心动图检查:在暂时停用丙吡胺后以及服用丙吡胺2.5小时后。结果:19名患者纳入研究。丙吡胺对左心室的影响并不一致。服用丙吡胺后,丙吡胺服用前平均整体应变峰值为−17±2%,服用后为−14±2%(p<0.0001)。基底间隔(p = 0.015)、基底下壁(p = 0.019)、基底后壁(p = 0.05)、心尖前壁(p = 0.0001)和心尖侧壁节段(p = 0.021)的应变显著降低。在所有其他节段,没有显著变化。丙吡胺还导致基底-心尖应变梯度显著增大(p = 0.036)。圆周应变和左心房应变未见变化。虽然左心室射血分数和流出道梯度没有变化,但整体和节段纵向应变的显著降低表明丙吡胺对HOCM患者心肌有急性负性肌力作用。结论:应变分析可能是评估心血管药物对HOCM患者左心室负性肌力作用的有用工具。